MedPath

Ultrasound Guided Psoas Compartment Block vs Suprainguinal Fascia Iliaca Compartment Block

Not Applicable
Conditions
Pain, Postoperative
Hip Dysplasia
Interventions
Registration Number
NCT05543109
Lead Sponsor
Tanta University
Brief Summary

The aim of this study was to compare the intraoperative and the postoperative analgesic effect of psoas compartment block (PCB) and supra-inguinal fascia iliaca compartment block (SFIB) in pediatric patients undergoing developmental dysplasia of the hip

Detailed Description

All subjects after entering operation room will be connected to standard monitor electrocardiograph, non-invasive blood pressure, heart rate, oxygen saturation.

Three mg/kg of propofol, 0.2 μg/kg of fentanyl and 0.1 mg/kg midazolam will be used for sedation. Oxygen at the concentration of 100% will be administrated under the mask in all patients after satisfactory sedation, tracheal intubation will be performed after intravenous anesthesia with administration of 3 mg/kg of propofol, 0.6 μg/kg of fentanyl and 0.9 mg/kg of rocurium. After intubation 2-3% of sevoflurane and 0.2-0.3 mcg/kg/min of fentanyl will be used to maintain anesthesia guided by PSI and hemodynamic monitoring.

The two groups will receive nerve block with local anesthetics. In the SFIB group, the patients will receive ultrasound-guided SFIB, while the patients in the PCB group will receive PCB under the guidance of ultrasound.

Local anesthetic 0.25% Ropivacaine will be used at 1 ml/kg for SFIB and PCB. (the dose of local anesthetic for SFIB or PCB was not more than 35ml). All blocks will be performed by the same experienced anesthesiologist.

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
85
Inclusion Criteria
  • Patients undergoing undergo acetabuloplasty
  • Anesthesiologists (ASA) physical status of I to II
Exclusion Criteria
  • Known allergy to local anesthetic
  • Infection at the block site.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Psoas compartment blockFentanylAfter induction of anesthesia; ultrasound guided psoas compartment block will be done using ropivacaine 0.25% 1ml/kg.
Suprainguinal fascia iliaca compartment blockFentanylAfter induction of anesthesia; ultrasound guided suprainguinal fascia iliaca compartment block will be done using ropivacaine 0.25% 1ml/kg.
Psoas compartment blockPropofolAfter induction of anesthesia; ultrasound guided psoas compartment block will be done using ropivacaine 0.25% 1ml/kg.
Psoas compartment blockRopivacaineAfter induction of anesthesia; ultrasound guided psoas compartment block will be done using ropivacaine 0.25% 1ml/kg.
Psoas compartment blockRocuroniumAfter induction of anesthesia; ultrasound guided psoas compartment block will be done using ropivacaine 0.25% 1ml/kg.
Psoas compartment blockSevofluraneAfter induction of anesthesia; ultrasound guided psoas compartment block will be done using ropivacaine 0.25% 1ml/kg.
Suprainguinal fascia iliaca compartment blockPropofolAfter induction of anesthesia; ultrasound guided suprainguinal fascia iliaca compartment block will be done using ropivacaine 0.25% 1ml/kg.
Suprainguinal fascia iliaca compartment blockRocuroniumAfter induction of anesthesia; ultrasound guided suprainguinal fascia iliaca compartment block will be done using ropivacaine 0.25% 1ml/kg.
Suprainguinal fascia iliaca compartment blockSevofluraneAfter induction of anesthesia; ultrasound guided suprainguinal fascia iliaca compartment block will be done using ropivacaine 0.25% 1ml/kg.
Suprainguinal fascia iliaca compartment blockRopivacaineAfter induction of anesthesia; ultrasound guided suprainguinal fascia iliaca compartment block will be done using ropivacaine 0.25% 1ml/kg.
Primary Outcome Measures
NameTimeMethod
Postoperative analgesic requirements8 hours

Postoperative Ketoprofen and morphine consumption

Intraoperative anesthetic requirement1 hour

Intraoperative anesthetic requirement including intraoperative sevoflurane concentration and total fentanyl consumption

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Mona Mohamed Mogahed

🇪🇬

Tanta, Elgharbia, Egypt

© Copyright 2025. All Rights Reserved by MedPath